Jade Biosciences, Inc. (JBIO) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated November 13, 2025, covers the announcement of financial results for the quarter ended September 30, 2025. The Company, formerly Aerovate Therapeutics, Inc., completed a business combination with Pre-Merger Jade on April 28, 2025, and subsequently changed its name to Jade Biosciences, Inc.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release furnished as Exhibit 99.1, which is referenced but not included in the provided text.
Material Changes and Corporate Events
- Business Combination: On April 28, 2025, the Company consummated a merger with Pre-Merger Jade. Pre-Merger Jade merged into a subsidiary of Aerovate, which then merged into Aerovate, with Aerovate changing its name to Jade Biosciences, Inc.
- Reverse Stock Split: Immediately prior to the merger closing, Aerovate effected a 1-for-35 reverse stock split of its common stock.
- Exchange Ratio: Pre-Merger Jade common stock and pre-funded warrants were converted into Company Common Stock and pre-funded warrants at an exchange ratio of 0.6311 shares of Company Common Stock for each share of Pre-Merger Jade common stock.
- Financial Statement Adjustments: Audited financial statements of Pre-Merger Jade have been retroactively adjusted to reflect the Exchange Ratio and are filed as Exhibit 99.2.
Guidance, Outlook, and Risks
The filing text does not contain specific management commentary, forward-looking guidance, risk factors, or details on unusual items. The Company directs readers to the press release (Exhibit 99.1) for the full announcement of financial results. The filing explicitly states that the results of operations and financial condition are furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q3 2025 revenue, net loss, and cash position figures.
- Verify the impact of the 1-for-35 reverse stock split on historical share counts and per-share metrics.
- Examine Exhibit 99.2 for the retroactively adjusted audited financial statements of Pre-Merger Jade.
- Confirm the current status of the Company's cash runway and burn rate post-merger.